Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04702503 | Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL) | PHASE1 | COMPLETED | 5 | — | — | Mar 8, 2019 | Nov 15, 2020 | Jan 11, 2021 | 1 | Poland |
Safety will be evaluated by reported adverse events
| Arm | Type | Description |
|---|---|---|
| 10% WP1220 ointment | EXPERIMENTAL | 10% WP1220 ointment topically applied 2x day for 84 days |
| Name | Type | Description |
|---|---|---|
| WP1220 | DRUG | Topical administration 2x daily for 84 consecutive days |
Inclusion Criteria: 1. Age ≥ 18 years at the time of signing informed consent. 2. Clinical diagnosis of MF. 3. Stage IA, IB, IIA, IIB, or II MF: T1-T4 with measurable lesions 4. Previously treatment with at least one standard therapy used to treat Stage IA, IB, IIA, IIB, or III MF. 5. Measurable sk...